High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma

Zhiying Xu; Yidong Liu; Yuanfeng Yang; Jieti Wang; Guodong Zhang; Zheng Liu1; Hangcheng Fu; Zewei Wang; Haiou Liu; Jiejie Xu

doi:10.18632/oncotarget.13692

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma

Zhiying Xu, Yidong Liu, Yuanfeng Yang, Jieti Wang, Guodong Zhang, Zheng Liu1, Hangcheng Fu, Zewei Wang, Haiou Liu and Jiejie Xu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:7548-7558. https://doi.org/10.18632/oncotarget.13692

Metrics: PDF 1777 views | HTML 2001 views | ?

Abstract

Zhiying Xu1,*, Yidong Liu1,*, Yuanfeng Yang2,*, Jieti Wang1, Guodong Zhang1, Zheng Liu1, Hangcheng Fu1, Zewei Wang1, Haiou Liu3, Jiejie Xu1

1Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

2Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

3Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Hospital of Obstetrics and Gynecology, Fudan University, Shanghai 200011, China

*These authors contributed equally to this work

Correspondence to:

Haiou Liu, email: [email protected]

Jiejie Xu, email: [email protected]

Keywords: clear-cell renal cell carcinoma, MUC13, overall survival, recurrence-free survival, prognostic biomarker

Received: July 06, 2016 Accepted: November 22, 2016 Published: November 29, 2016

ABSTRACT

Background: Mucin13 (MUC13) is a transmembrane glycoprotein that is aberrantly expressed in ovarian and gastro-intestinal tumors, but its role in renal cell carcinoma remains elusive. The purpose of this study is to evaluate the prognostic value of MUC13 expression in patients with non-metastatic clear cell renal cell carcinoma (ccRCC) after surgical resection.

Results: MUC13 high expression was associated with high Fuhrman grade (p < 0.001), high SSIGN score (p = 0.011), early recurrence (p < 0.001) and poor survival (p < 0.001). Multivariate Cox regression analysis identified MUC13 expression as an independent prognostic factor for RFS and OS of ccRCC patients. A nomogram integrating MUC13 expression and other independent prognosticators was established to predict RFS and OS of ccRCC patients. Optimal agreement was shown between the predictions and observations in calibration curves.

Matrials and methods: This study enrolled 410 postoperative non-metastatic ccRCC patients at a single institution. Clinicopathologic variables, recurrence-free survival (RFS), and overall survival (OS) were recorded. MUC13 expression was detected by immunohistochemical staining in tumor specimens. Association of MUC13 expression with clinicopathological factors was explored. Kaplan-Meier analysis was performed to compare survival curves. Univariate and multivariate Cox regression models were used to analyze the impact of prognostic factors on RFS and OS. A prognostic nomogram was constructed based on the independent prognostic factors identified by multivariate analysis.

Conclusions: MUC13 high expression is a novel independent adverse prognostic factor of clinical outcome in non-metastatic ccRCC patients after surgery.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13692

Publication Alerts

Research Papers:

High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma

Abstract